Trial · NCT07910968
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Therapeutic Optimization Opportunities Achieved | 9 months | Proportion of eligible therapeutic optimization opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible opportunities. Each therapeutic swap includes two opportunities: discontinuation of a potentially inappropriate medication and initiation of the corresponding evidence-based medication. Individual patients may contribute multiple opportunities. |
| Secondary | Proportion of Implementation Optimization Opportunities Achieved | 9 months | Proportion of eligible implementation opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible implementation opportunities. Implementation refers to initiation of the corresponding evidence-based medication. Individual patients may contribute multiple opportunities. This will be assessed overall and by SWAP type. |
| Secondary | Proportion of De-implementation Optimization Opportunities Achieved | 9 months | Proportion of eligible de-implementation opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible de-implementation opportunities. De-implementation refers to discontinuation of a potentially inappropriate or harmful medication. Individual patients may contribute multiple opportunities. This will be assessed overall and by SWAP type. |
| Secondary | Proportion of Patients With Polypharmacy | 9 & 18 months | Proportion of patients with polypharmacy, defined as concurrent use of five or more medications at the 9-month and 18-month assessments. |
| Secondary | Proportion of Patients With Hyper-polypharmacy | 9 & 18 months | Proportion of patients with hyper-polypharmacy, defined as concurrent use of ten or more medications at the 9-month and 18-month assessments. |
| Other | Number of Participants With All-Cause Hospitalization | 9 & 18 months | Number of participants experiencing at least one hospitalization for any cause during the follow-up period, identified using electronic health record data. |
| Other | Number of Participants with All-Cause Mortality | 9 & 18 months | Number of participants who died from any cause during the follow-up period, ascertained using routinely collected health system data. |
| Other | Proportion of Eligible Patients Included in SWAP-CKM | 9 & 18 months | Proportion of patients included in SWAP-CKM among all patients meeting study eligibility criteria within Kaiser Permanente Northern California. Reach will also be characterized across demographic and clinical subgroups. |
| Other | Proportion of Eligible Therapeutic Swaps Adopted by Clinicians | 9 & 18 months | Proportion of eligible therapeutic swaps adopted by clinicians, defined as the number of recommended swaps implemented divided by the total number of eligible swaps. Adoption will be evaluated across patient characteristics, clinician types, and therapeutic swap categories. |
| Other | Number of SWAP-CKM Electronic Advisory Firings | 9 & 18 months | Total number of SWAP-CKM electronic OurPractice Advisory (OPA) firings recorded during the study period, summarized over time to assess patterns of intervention maintenance and health system learning. |
| Other | Proportion of Long-term Therapeutic Optimization Opportunities Achieved | 18 months | Proportion of eligible therapeutic optimization opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible opportunities. Each therapeutic swap includes two opportunities: discontinuation of a potentially inappropriate medication and initiation of the corresponding evidence-based medication. Individual patients may contribute multiple opportunities. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07910968/registered